Lung cancer screening using low-dose CT scans in women
Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study
This study is testing if low-dose CT scans can help find lung cancer earlier in women aged 50 to 74 who have a history of smoking, by comparing how well different radiologists read the scans and seeing if artificial intelligence can help too.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2635 (estimated) |
| Ages | 50 Years to 74 Years |
| Sex | Female |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT05195385 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of low-dose thoracic CT scans for lung cancer screening in women aged 50 to 74 with a significant smoking history. It will compare the performance of a single trained general radiologist reading the scans against double readings by expert radiologists. Additionally, the study will assess the role of artificial intelligence in aiding the detection of lung nodules. Participants will undergo baseline, 1-year, and 2-year follow-up scans to monitor for lung cancer signs.
Who should consider this trial
Good fit: Ideal candidates are women aged 50 to 74 with a smoking history of at least 20 pack-years who have quit smoking within the last 15 years.
Not a fit: Patients with current symptoms suggesting malignancy, ongoing infections, or a history of lung cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve early detection of lung cancer in women, potentially reducing mortality rates.
How similar studies have performed: Previous studies have shown that low-dose CT screening can significantly reduce lung cancer mortality, but this specific approach using general radiologists and AI is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women aged from 50 to 74 years * who had smoked at least 20 pack years and quit less than 15 years ago * Had given their consent and accepted the need for a 2-year follow-up * Affiliated to the social security system Exclusion Criteria * Presence of clinical symptoms suggesting malignancy (weight loss, hemoptysis) or ongoing infection (cough with fever) * Evolving cancer * History of lung cancer * A 2-year follow-up not possible * Chest CT scan performed within 2 years prior to inclusion
Where this trial is running
Paris
- Hôtel-Dieu — Paris, France (Recruiting)
Study contacts
- Principal investigator: Marie-Pierre REVEL, PhD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Marie-Pierre REVEL, PhD
- Email: marie-pierre.revel@aphp.fr
- Phone: +33 1 42 34 79 10
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.